7/102 sources · 2 publishersUpdated Nov 13, 13:32 UTC
Stifel lifts SpyGlass Pharma price target to $44 while retaining Buy rating
Stifel raised its price target for SpyGlass Pharma from $42 to $44 and continued to rate the shares Buy. The revision followed the company’s third-quarter 2026 results and a management discussion at the 2026 Stifel Healthcare Conference. Stifel said its higher probability assessment for BIM-DRS, after the start of its first-in-human study, contributed to the change.
Why it matters
The higher target and unchanged Buy rating provide a more bullish valuation view from Stifel. The analyst’s revised BIM-DRS probability assessment is the stated driver of the target increase.
Key facts
- 1Stifel’s price target moved to $44 from $42 while its Buy rating remained unchanged. investing.com
- 2SpyGlass Pharma’s third-quarter 2026 results were released on November 12. investing.com
- 3Stifel’s probability-of-success adjustment followed the start of BIM-DRS’s first-in-human study. investing.com
- 4The target increase implies 32.1% upside from SpyGlass Pharma’s Nov 12 close of $33.32. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.